Last reviewed · How we verify
HIP2B
At a glance
| Generic name | HIP2B |
|---|---|
| Sponsor | CureDM |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of Subcutaneous Doses of HIP2B in Subjects With Type 2 Diabetes Mellitus Treated With Metformin (PHASE1)
- A Study of Subcutaneous Doses of HIP2B in Healthy Male Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HIP2B CI brief — competitive landscape report
- HIP2B updates RSS · CI watch RSS
- CureDM portfolio CI